Abstract: GABA C receptors belong to the nicotinicoid superfamily of ionotropic receptors that include nicotinic acetylcholine receptors, bicuculline-sensitive GABA A receptors, strychnine-sensitive glycine receptors and 5HT3 serotonin receptors. The GABA C receptor concept arose from medicinal chemical studies of a conformationally restricted analog of GABA. Receptors matching the predicted properties of GABA C receptors were cloned from the retina. Post cloning studies revealed the unique physiology and pharmacology of these relatively simple homomeric receptors. Three subtypes of GABA C receptors have been cloned from mammalian sources and pharmacological differences between the ρ1, ρ2 and ρ3 GABA C receptors have been described. There is evidence for functional GABA C receptors in the retina, spinal cord, superior colliculus, pituitary and the gut and their involvement in vision, aspects of memory and sleep-waking behaviour. This review concentrates on the medicinal chemistry and molecular pharmacology of GABA C receptor subtypes emphasising possible new investigational tools with which to investigate further GABA C receptor function. The most useful currently available ligands that show some GABA C receptor subtype selectivity are TPMPA, P4PMA, imidazole-4-acetic acid, 2-methyl-TACA and (±)-TAMP.
INTRODUCTION
bicuculline-sensitive, and GABA B receptors that were bicuculline-insensitive and activated by baclofen. The GABA molecule can adopt a variety of different low energy conformations. The design and development of GABA analogs of restricted conformation showed that different conformations of GABA were likely to interact with different macromolecules that recognise GABA in its function as an inhibitory neurotransmitter [1] . A key compound was cis-4-aminocrotonic acid (CACA), a conformationally restricted analog of GABA held in a range of folded conformations (Fig. 1) . In 1975, CACA was shown to have an inhibitory action on the firing of neurons in the spinal cord that was pharmacologically different to the predominant action of GABA on these neurons in that the It is now known that GABA A and GABA B receptors are fundamentally different types of receptors. GABA A receptors are ligand-gated ion channels made up of a pentameric mixture of protein subunits [4] , while GABA B receptors are heterodimeric G-protein coupled receptors [5] . But what of CACA, the GABA analog that apparently did not interact with either GABA A or GABA B receptors, described as a 'disturber of the peace' by Krogsgaard-Larsen and colleagues [6] ? The concept of a third major class of GABA receptors arose in 1984 from studies on the lack of effect of CACA on the binding of radioactive baclofen to rat cerebellar membranes: "folded analogs of GABA may interact with a class of binding site (GABA C ?) insensitive to (-)-baclofen and bicuculline." [7] H2N COOH H2N
COOH

CACA GABA
The expression of GABA receptors with novel properties in oocytes injected with polyA + RNA from mammalian retina [8] , and the cloning of ρ1-and ρ2-subunit cDNAs from a human retinal library [9, 10] , represented major breakthroughs in the understanding of GABA C receptors. Expressed in Xenopus oocytes, the ρ-subunits formed homooligomeric GABA-activated chloride channels insensitive to bicuculline but sensitive to CACA. The expression of retinal polyA + RNA in oocytes led to GABAactivated chloride currents made up of two distinct components, one mediated by GABA A receptors and the other mediated by GABA C receptors, thus providing evidence that the protein subunits making up these different receptor populations associate independently of each other. Subsequent studies on the self-associating ρ-subunits action of CACA was insensitive to the GABA antagonist bicuculline [2] . In 1981, Hill and Bowery [3] showed that another GABA analog, baclofen, also had a bicucullineinsensitive action on neurons, and proposed that there were two types of GABA receptors: GABA A receptors that were expressed in oocytes and COS cells have provided extensive evidence that these subunits form GABA receptors with physiological and pharmacological properties distinct from those of heterooligomeric GABA A receptors [11] [12] [13] [14] [15] .
of ρ-subunits. To date, at least five different ρ−subunits have been cloned, including three from humans (ρ1, ρ2 and ρ3) [9, 10, 24] with two ρ1 splice variants [25] , three from rat (ρ1−3) [26] [27] [28] [29] , two from chick (ρ1 and ρ2) [30] , five from white perch (ρ1Α, ρ1Β, ρ2Α, ρ2Β and ρ3) [31] , and two from mouse (ρ1 and ρ2) retinae [32] . Functional evidence for the existence of native GABA C receptors came in 1993 with back-to-back papers in Nature reporting that bicuculline-insensitive actions of GABA were mimicked by CACA in rat retinal bipolar cells [16] and in white perch rod-driven retinal horizontal cells [17] . The pharmacological properties of these responses closely resembled those observed for recombinant GABA C receptors resulting from retinal mRNA expressed in oocytes.
The use of reverse transcriptase PCR and in situ hybridisation techniques has shown that ρ1 mRNA is located predominantly in the retina, whereas ρ2 mRNA is more widely distributed in the CNS. In humans, the ρ2 subunit is present in most brain regions, including the cerebellum, thalamus and temporal and frontal cortices [33] . In rat brain, ρ3 mRNA expression pattern is different to the expression pattern of ρ1 and ρ2 mRNA's with lower expression levels of ρ3 mRNA in the retina and stronger expression levels in the hippocampus [34] . Outside the CNS, GABA C ρ1 and ρ2 receptors have also been found associated with specific neurons in the gut [35, 36] . Truncated ρ1 and ρ2 mRNAs have been described in thyrotropin-secreting cells in the pituitary together with GABA C -like receptors that differ from those found in the retina [37] .
GABA C receptors belong to the nicotinicoid superfamily of ligand-gated ion channels that include nicotinic acetylcholine receptors, 5-HT 3 receptors, GABA A receptors, strychnine-sensitive glycine receptors and some invertebrate anionic glutamate receptors [18] . The most studied and best understood of this class of receptors is the nicotinic acetylcholine receptors, while the GABA A receptors appear to be the most complex and the GABA C receptors the simplest. Members of the nicotinicoid superfamily are considered to be pentamers made up of protein subunits likely to have been derived from a common ancestor [19] .
Pharmacological differences between recombinant ρ1, ρ2 and ρ3 GABA C receptors are emerging which may aid in assessing the functional relevance of these GABA C receptor subtypes in various tissues. Recent reviews of GABA C receptors have emphasised their structure and function from a molecular biological perspective highlighting their structural characteristics, identifying structural domains, noting the chromosomal localisation of GABA C subunit genes and resulting link to diseases, identifying GABA C receptor associated proteins and cloning new splice variants [20] [21] [22] . This review concentrates on the medicinal chemistry and molecular pharmacology of GABA C receptor subtypes emphasising possible new investigational tools with which to investigate further GABA C receptor function.
TPMPA -THE FIRST SELECTIVE GABA C ANTA-GONIST
TPMPA,
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (Fig. 2) , was the first selective GABA C antagonist to be developed [38, 39] . It arose from the finding that isoguvacine has activity at both GABA A and GABA C receptors but no activity at GABA B receptors, indicating that the tetrahydropyridine ring of isoguvacine (Fig. 2) distinguishes GABA B from GABA C receptors but does not distinguish GABA A from GABA C receptors. Combining this with the knowledge that a methylphosphinic acid group, SIMILARITIES AND DIFFERENCES BETWEEN GABA A AND GABA C RECEPTORS GABA A and GABA C receptors are subfamilies of the nicotinicoid superfamily of ligand gated ion channels [18] . The protein subunits that make up the GABA A and GABA C receptor subfamilies show up to 36% optimised sequence identity overall and up to 73% sequence identity in the membrane spanning regions. They are clearly derived from common ancestral proteins in the nicotinicoid superfamily. The GABA A and GABA C subfamilies can be distinguished on the basis of their different channel properties, the availability of selective agonists, antagonists and modulators, the different chromosomal localisation of the genes coding for the protein subunits of the two subfamilies and the reluctance of these subunits to co-express in functional receptors, and the different proteins that anchor the protein complexes to the cytoskeleton [21, 23] . GABA C receptors are considered to be both homooligomeric and pseudohetero-oligomeric receptors comprised as in the potent GABA B agonist 3-APMPA (Fig. 2) [40] interacts with GABA C [12] but not with GABA A receptors led to TPMPA, which incorporates both the tetrahydropyridine ring system and a methylphosphinic moiety [38, 39] .
weaker (EC 50 139 µM) and less efficacious (57%) at rat ρ3 receptors expressed in Xenopus oocytes [43] .
It is now known that CACA has other actions in addition to being a partial agonist at GABA C receptors. Uptake studies have shown that CACA acts as a weak inhibitor of β-alanine transport in rat cerebral cortex slices [52] . It appears to be a weak substrate for a transporter that transports GABA, β-alanine and nipecotic acid in glial cells isolated from guinea-pig retina [53] . CACA stimulates the passive release of [ 3 H]GABA and [ 3 H]β-alanine by heteroexchange from slices of rat cerebellum, cerebral cortex and spinal cord, without influencing potassium-evoked release [54] . CACA is only ten times weaker as a substrate for the transporter than as a partial agonist at the GABA C receptors. This transporter may be related to the GAT-3 protein, a GABA transporter located predominantly on glial cells in the CNS [54] .
TPMPA is more that 100 times more selective in blocking ρ1 GABA C receptors than in blocking GABA A receptors from rat cerebral cortex polyA + RNA expressed in Xenopus oocytes [39] . At GABA B receptors, TPMPA is a weak agonist when measured by whole-cell patch recordings from pyramidal neurons in rat hippocampal slices [39] . TPMPA is greater than 500 times more selective in blocking ρ1 GABA C receptors expressed in Xenopus oocytes than in activating GABA B receptors [39] .
TPMPA has been shown to block responses in the neonatal rat spinal cord providing evidence for the involvement of GABA C receptors in synaptic transmission in this tissue [41] .
In addition to its agonist action on GABA C receptors in the retina, CACA has been shown to influence calcium currents at lower concentrations than those that activate GABA-evoked chloride currents [55] .
TPMPA shows some subunit selectivity being 8-times weaker at human recombinant ρ2 than at ρ1 GABA C receptors expressed in Xenopus oocytes [42] . At rat recombinant ρ3 GABA C receptors, TPMPA was 2-times weaker than at human recombinant ρ1 GABA C receptors [43] . The ρ1δ51 splice variant of ρ1 GABA C receptors was more sensitive to TPMPA than are ρ1 GABA C receptors [44] .
CACA has been shown to weakly activate GABA A receptors that contain α6 subunits on rat cerebellar granule cells and on recombinant α6β2γ 2S GABA A receptors expressed in HEK cells [56] . This action of CACA was apparent at 30 µM CACA, did not saturate at 1 mM, was abolished by 100 µM bicuculline and was insensitive to 100 µM TPMPA. The piperidine analog of TPMPA, P4MPA ((piperidine-4-yl)methylphosphinic acid) is a more potent antagonist of human recombinant ρ2 GABA C receptors than is TPMPA [45, 46] , but weaker than TPMPA at human recombinant ρ1 and rat recombinant ρ3 GABA C receptors [43] .
Thus it appears that studies using CACA as a selective GABA C receptor partial agonist should be interpreted with caution.
TPMPA has been used to study GABA C receptor function in the retina [47, 48] , spinal cord [41] , superior colliculus [49] , and gut [35] , and the involvement of GABA C receptors in memory consolidation [45, 46] and sleep-waking behaviour [50] .
(+)-CAMP -A SELECTIVE GABA C RECEPTOR AGONIST
The (+)-isomer of CAMP, (1S,2R)-2-aminomethylcyclopropanecarboxylic acid, may be a superior GABA C receptor agonist to CACA [57] . Racemic CAMP has been widely investigated for its effects on a variety of GABA receptors. CAMP is a conformationally restricted analog of GABA held in a range of folded conformations similar to those available to CACA. Conformational restriction in CAMP is achieved via a cyclopropane ring, rather than a cis double bond as in CACA; this has less influence on the ionisation of the carboxyl group, which in CACA is made more acidic by the double bond.
CACA -THE PROTOTYPE GABA C AGONIST
CACA, cis-4-aminocrotonic acid, was the prototype GABA C agonist, shown to be an inhibitor of neuronal firing insensitive to the GABA A antagonist bicuculline [2] that did not influence the binding of the GABA B agonist baclofen to brain membranes [7] . Functional studies of the effects of CACA in a variety of neuronal preparations linked CACA to receptors that are activated by GABA and are distinct from the classical GABA A and GABA B receptors and led to widespread interest in GABA C receptors [11, 12, 16, 17] . CACA was shown to be a moderately potent partial agonist at GABA C receptors. TACA, the trans-isomer of CACA, was considerably more potent as an agonist at GABA C receptors but less selective in that TACA was also a potent agonist at GABA A receptors, and a substrate for GABA-T [2] . CACA showed similar potency as a partial agonist at human ρ1 and ρ2 receptors expressed in Xenopus oocytes (EC 50 (ρ1) = 74 µM; EC 50 (ρ2) = 70 µM) and showed 70-80% of the efficacy of GABA [13, 51] . It appeared to be CAMP is a moderately potent full agonist at human ρ1 and ρ2 GABA C receptors (Kd 65 µM at ρ1 and Kd 104 µM at ρ2) [57] and a partial agonist (EC 50 53 µM, I max 57%) at rat ρ3 GABA C receptors [43] . CAMP has no effect in inhibiting [ 3 H]GABA uptake in cortical slices and thus may be the most selective agonist at GABA C receptors currently available [58] .
Resolution of CAMP into its optical isomers by separation of diastereoisomeric esters [59] afforded (+)-and (-)-CAMP (Fig. 3) , which surprisingly showed opposite pharmacology at GABA C receptors [57] . (+)-CAMP was a relatively potent full agonist (Kd 40 µM at ρ1 and Kd 27 µM at ρ2), while (-)-CAMP was a weak antagonist (IC 50 900 µM at ρ1 and 400 µM at ρ2). Rarely do enantiomers have identical biological properties, but it is also relatively uncommon to find them exerting opposite pharmacological effects. Neither isomer of CAMP influenced GABA transport [57] .
has been used to characterise GABA C receptors in rat pelvic ganglia [64] . Species differences have been noted in the effects of imidazole-4-acetic acid on GABA C receptors in the retina [65] .
2-METHYL-TACA
2-Methyl-TACA, trans-4-amino-2-methylbut-2-enoic acid (Fig. 4) , shows contrasting pharmacological properties at ρ1 and ρ2 GABA C receptors [42] . It is a competitive antagonist at human ρ1 GABA C receptors (Kb 45 µM) and a partial agonist at human ρ2 GABA C receptors (Kd 101 µM, I max 34%) and thus may be useful in differentiating between homo-oligomeric ρ1 and ρ2 receptors in native tissues. (Fig.  2) , a GABA A receptor agonist [67] and GABA C receptor partial agonist. The increased conformational flexibility of 2-methyl-TACA may be a factor in the ability of 2-methyl-TACA to stimulate human ρ2 GABA C receptors. Fig. (3) . Structures of (+)-CAMP, a selective GABA C receptor agonist and of (-)-CAMP, a GABA C receptor antagonist.
(+)-CAMP is a weak antagonist at human α1β2γ 2L GABA A receptors expressed in oocytes, 1 mM producing 30% inhibition of the current produced by 10 µM GABA [57] .
It has yet to be tested on recombinant α6β2γ 2S GABA A receptors that are activated by CACA [56] .
TAMP, (+)-TACP AND (+)-4-ACPCA
IMIDAZOLE-4-ACETIC ACID
TAMP, trans-2-aminomethylcyclopropanecarboxylic acid (Fig. 5) , in its racemic form has long been known as a GABA A [58] and GABA C receptor partial agonist [13] . Separated into its optical isomers, (-)-TAMP is more potent against ρ2 GABA C receptors (Kd 3 µM, I max 50%) than against ρ1 GABA C receptors (Kd 9 µM, I max 40%) or Imidazole-4-acetic acid is a naturally occurring metabolite of histidine that activates GABA A receptors [60] . It is an analog of GABA where the amino group of GABA has been replaced by an imidazole ring (Fig. 4) . It penetrates the blood-brain barriers on systemic administration and reduces blood pressure and heart rate by stimulating central GABA A receptors [61] . Inhibitors of histamine methylation in the brain promote formation of imidazole-4-acetic acid [62] . It is a partial agonist at GABA C receptors showing a 12-fold higher intrinsic activity at ρ2 than at ρ1 receptors (EC 50 16 µM, I max 3% at ρ1; EC 50 3 µM, I max 38% at ρ2) [13, 42, 51] . It is a potent antagonist at ρ1 GABA C receptors (K B 1.5 µM), with an affinity similar to that of GABA [42] . It is also an antagonist (K B 13 µM) at ρ3 GABA C receptors [43] .
Imidazole-4-acetic acid may be a useful compound for distinguishing between ρ1, ρ2 and ρ3 GABA C receptors when used in conjunction with other substances. Although it has a complex pharmacology [63] , imidazole-4-acetic acid α1β2γ 2L GABA A receptors (Kd 50 µM, I max 50%), while (+)-TAMP is weaker than (-)-TAMP at all 3 receptors (Kd 30 µM, I max 60% at ρ2; Kd 60 µM, I max 40% at ρ1; and Kd 500 µM, I max 50% at α1β2γ 2L) [57] . It has been shown recently that (±)-TAMP has no agonist properties at rat ρ3 GABA C receptors, but it is a potent antagonist (Kb 5 µM) at these receptors [43] . Thus (-)-TAMP may be a useful agent with which to distinguish ρ3 from ρ1 and ρ2 GABA C receptors, when used in combination with other agents.
psychoactive, while THIP is a potent analgesic. Side effects of THIP (including sedation, dizziness, and blurred vision) meant that it had too low a therapeutic index to be therapeutically useful as an analgesic [74, 75] . There is renewed interest in THIP with respect to sleep therapy as it produces slow wave sleep and reduces spindling activity in non rapid eye movement sleep in humans [76] .
THIP-induced analgesia is not sensitive to bicuculline indicating that GABA A receptors are not involved [77] . Perhaps the GABA C receptor antagonist action of THIP contributes to its analgesic action? Benzodiazepine-sensitive GABA A receptors do not appear to be involved in the effects of THIP on sleep patterns [76] . As noted above, the GABA C receptor antagonist TPMPA has been used to probe the involvement of GABA C receptors in sleep-waking behaviour [50] .
Early studies on (+)-TACP, (+)-trans-3-aminocyclopentanecarboxylic acid (Fig. 5) , showed that it was a potent inhibitor of the firing of cat spinal interneurones whose inhibitory action could not be blocked completely by the GABA A receptor antagonist bicuculline [68] . Studies on radiolabelled (+)-TACP binding to rat brain membranes showed a high affinity binding component that could be inhibited by CACA suggesting that (+)-TACP could bind to GABA C receptors [69] . Recent studies have shown that (+)-TACP is a potent partial agonist at ρ1, ρ2 and ρ3 receptors (EC 50 s 2.7, 1.5 and 2.7 µM; I max 83, 85 and 27% respectively) [43, 70] .
CGP36742
CGP36742, 3-aminopropyl-n-butylphosphinic acid (Fig.  5) is one of a range of phosphinic acid analogs of GABA that act as GABA C receptor antagonists [72] . CGP36742 was developed as an orally active GABA B receptor antagonist [40, 78] . It inhibited the binding of CGP27492 to GABA B receptors on rat brain membranes with an IC 50 of 38 µM [40, 78] and had much weaker effects on binding to GABA A receptors (IC 50 500 µM) [79] . Furthermore, CGP36742 had no effect on a range of other receptors at 1 mM, including benzodiazepine, muscarinic cholinergic, adrenergic, serotonergic, histaminergic, NMDA, quisqualate and kainate receptors.
(+)-4-ACPCA, (+)-4-aminocyclopent-1-ene-1-carboxylic acid (Fig. 5) , a GABA A receptor agonist [71] is an antagonist at ρ1 and ρ2 GABA C receptors (Ki 6 and 5 µM respectively) [70] .
The structures of these and related compounds provide clues as to how they bind to GABA C receptors to exert their agonist and antagonist actions [43, 70, 72] .
MUSCIMOL AND THIP
Functional studies on ρ1 GABA C receptors expressed in oocytes showed however that CGP36742 acted as a GABA C receptor antagonist with an IC 50 = 62 µM, i.e. approximately half as potent as against GABA B receptors [72] .
Muscimol and THIP (Fig. 5) are widely used as selective GABA A receptor agonists [4]. However they have potent actions on GABA C receptors which means that interpretation of studies with these agents should be treated with some caution. No "selective" GABA A receptor agonist is known that does not have significant action on either GABA B and/or GABA C receptors.
CGP36742 has shown promising therapeutic potential for the treatment of cognitive deficits, petit mal epilepsy and depression [79] [80] [81] [82] [83] . As not all orally active GABA B antagonists show this therapeutic potential [78] , it is possible that antagonism of GABA C receptors contributes to these effects [45, 72] .
Muscimol, a conformationally restricted analog of GABA in which a hydroxyisoxazole moiety replaces the carboxyl group of GABA [1] , is a potent partial agonist at human ρ1 and ρ2 GABA C receptors (Kd 2.3 and 1.4 µM respectively) expressed in oocytes [13, 51] . It shows similar potency (EC 50 1.9 µM) at rat ρ3 GABA C receptors [43] . Muscimol appears to be more potent at GABA C receptors than at GABA A receptors [12] .
BARBITURATES
Barbiturates have long been known to be able to enhance the action of GABA on GABA A receptors [84] but they appear to have no action on wild type GABA C receptors [13] . Indeed, chimeric constructs of β3 GABA A and ρ1 GABA C receptor subunits have been used to show that the residues of the β3 subunit involved in barbiturate binding to GABA A receptors are located downstream from the middle of the second membrane spanning region [85] . THIP, 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (Fig. 5) , is a conformationally restricted analog of muscimol [1] . It is a potent GABA A receptor partial agonist of high efficacy [67] , but has proved to be a moderately potent GABA C receptor antagonist (Kb 32 µM at GABA C receptors produced from bovine retinal poly(A) + RNA expressed in oocytes [12] and Kb 10 µM at rat ρ3 GABA C receptors [43] ).
Splicing of the third membrane spanning region of a β2 GABA A subunit into a ρ1 GABA C receptor subunit produces a chimera that is sensitive to barbiturates [86] . Mutation of a single tryptophan residue at position 328 Unlike GABA, both muscimol and THIP pass the bloodbrain barriers on systemic administration [73] . Muscimol is within the third membrane spanning domain of ρ1 GABA C receptor subunits to a variety of hydrophobic amino acids is sufficient to impart barbiturate sensitivity to ρ1 GABA C receptors [86] .
conditions where such steroids at nM concentrations modulated GABA A receptors [88] , it is now known that µM concentrations of steroids can modulate GABA C receptors [89] . The low affinity effects of neuroactive steroids on GABA C receptors are more apparent at low concentrations of GABA well below its EC 50 . Under such conditions, the anaesthetic agent alphaxalone, and the neurosteroids allopregnanolone and allotetrahydroxydeoxycorticosterone (5α-THDOC) (Fig. 6) enhanced GABA-evoked currents at ρ1 GABA C receptors expressed in oocytes and prolonged the decay time of these currents, i.e. they were positive modulators. At 20 µM, these steroids potentiated GABAevoked currents by 96%, 42% and 198% respectively. These are all 5α-steroids and are the first examples of agents able to positively modulate GABA C receptors.
The second membrane spanning region of ρ1 GABA C receptors can also be modified to confer barbiturate sensitivity on these receptors. Mutation of an isoleucine residue at position 307 to serine results in a mutant ρ1 GABA C receptor that can be positively modulated by barbiturates [87] .
Thus, it appears that two key amino acid residues (serine 307 and tryptophan 328) in ρ1 GABA C receptors are responsible for the lack of activity of barbiturates at these receptors, in contrast to the positive modulation and direct agonist action of barbiturates at GABA A receptors.
The related 5β-steroids (Fig. 6 ) -5β-dihydroprogesterone (IC 50 5 µM), pregnanolone (IC 50 0.55 M) and tetrahydrodeoxycorticosterone (5β-THDOC, IC 50 1 µM) -were negative modulators in that they inhibited GABAevoked currents at these ρ1 GABA C receptors [89] . Thus the configuration of the A/B ring junction in these steroids influences their action on GABA C receptors, the trans-
NEUROACTIVE STEROIDS
While early studies reported GABA C receptors to be insensitive to modulation by neuroactive steroids under configuration in the 5α-steroids being favourable to enhancing GABA action and the cis-configuration resulting in inhibition of GABA action. The low affinity effects of these neuroactive steroids on GABA C receptors are quite different from the high affinity effects typically observed with GABA A receptors [89] .
including the cerebellum, thalamus and temporal and frontal cortices; and the ρ3 subunit is found in the hippocampus.
Pharmacological differences between recombinant ρ1, ρ2 and ρ3 GABA C receptors are emerging which may aid in assessing the functional relevance of these GABA C receptor subtypes in various tissues. The structure-activity profiles of the GABA C receptor agonists and antagonists highlighted in this review provide leads for the design and development of subtype selective GABA C receptor ligands.
LORECLEZOLE AND (+)-ROD188
There are other agents, in addition to the 5β-steroids shown in Fig. 6 , that enhance the action of GABA on GABA A receptors and reduce the action of GABA on GABA C receptors. The anticonvulsant drug, loreclezole (Fig.  7) , is a positive modulator of GABA A receptors containing a β2 or β3 subunit [90] . This selectivity is determined by a single amino acid residue in the second membrane spanning region (β2Asn289, β3Asn290) which when converted to a serine residue (as in β1 subunits) leads to a 300-fold loss of potency of loreclezole as a positive modulator of GABA A receptors. Against ρ1 GABA C receptors, loreclezole is a potent negative modulator (IC 50 0.5 µM) that has been described as a simple functional marker for GABA C receptors [91] . Another positive modulator of GABA A receptors, (+)-ROD188 that is known to have a different mode of action to that of loreclezole [92] , is also a negative modulator (IC 50 100 µM) of ρ1 GABA C receptors [91] .
The most useful currently available GABA C subtype selective ligands appear to be: the GABA C antagonists TPMPA and P4MPA which show an order of potency ρ1 > ρ3 > ρ2 and ρ2 > ρ1 > ρ3 respectively; imidazole-4-acteic acid which is a potent partial agonist at ρ2 of moderate efficacy, a partial agonist of very low efficacy at ρ1 and an antagonist at ρ3; 2-methyl-TACA, which is an antagonist at ρ1 and a partial agonist at ρ2; and (±)-TAMP, which is a potent antagonist at ρ3 and a partial agonist at ρ1 and ρ2. While medicinal chemical studies on GABA C receptors are just beginning, it is already clear that GABA C receptors are very different from GABA A receptors in terms of agonist and antagonist structural profiles. Functional studies indicate the involvement of GABA C receptors in the retina, spinal cord, superior colliculus, pituitary and the gut. GABA C receptors are involved in vision and have been implicated in aspects of memory and sleep-waking behaviour. [6] Krogsgaard-Larsen, P.; Frølund, B.; Ebert, B. GABA-A receptor agonists, partial agonists, and antagonists. The GABA Receptors; Second ed.; Humana: Totowa, New Jersey, 1997; pp 37-81. There are at least 3 major subtypes of GABA C receptors found in mammals: the ρ1 subtype is located predominantly in the retina; the ρ2 subunit is found in most brain regions, [7] Drew, C. A.; Johnston, G. A. R.; Weatherby, R. P. Bicuculline-insensitive GABA receptors: studies on the binding of (-)-baclofen to rat cerebellar membranes. Neurosci. Lett. 1984, 52, 317-321.
